skip to Main Content

    Privacy Statement from Integrated Biotherapeutics Inc. 

    Integrated Biotherapeutics Inc. complies with all applicable laws and regulations relating to data protection and data privacy.  We will use the personal data you share with us only to send you the requested material and to communicate with you about our products and services special offers, subject to an opt out possibility.

    Back To Top
    ×Close search
    Search
    Fig. 1 Survival after challenge with INFV H1N1 A/Pert/261/2009 (Tamiflu-resistant strain). Inoculum 1xLD90=1.0E+05 PFU/mouse
    Survival after challenge with INFV H1N1 A/Pert/261/2009 (Tamiflu-resistant strain) 1.0E+05 PFU/mouse
    Survival and weight change in BALB/c mice challenged with INFV A/ Texas/36/91 (H1N1) and treated with antiviral Osletamivir Phosphate (Tamiflu)
    Lung viral load and Survival (30 % weight loss cut-off) in BALB/c mice challenged with INFV H3N2 A/HK/1/68.

    Alpha (UK) – B. 1.1.7 / 501Y.V1

    amino acid mutations: del69–70 HV, del144 Y, N501Y, A570D, D614G, P681H, T761I, S982A, D1118H

    Beta (South Africa) – B.1.351

    amino acid mutations: K417N, E484K, N501Y, D614G, A701V

    Gamma (Brazil) – P.1

    amino acid mutations: L18F, T20N, P26S, D138Y, R190S, K417T, E484K, N501Y, D614G, H655Y, T1027I

    Epsilon (Ca, USA) B.1.427

    amino acid mutations: L452R, D614G

    SARS-CoV-2 Parental Strain Wild Type (Wuhan)
    SARS-CoV-2 D614G Variant

    amino acid mutations: D614G

    Epsilon (Ca, USA) B.1.429

    amino acid mutations: S13I, W152C, L452R, D614G

    SARS-CoV-2 Delta Variant

    amino acid mutations: L452R, E484Q